JP2021526365A5 - - Google Patents

Info

Publication number
JP2021526365A5
JP2021526365A5 JP2020564560A JP2020564560A JP2021526365A5 JP 2021526365 A5 JP2021526365 A5 JP 2021526365A5 JP 2020564560 A JP2020564560 A JP 2020564560A JP 2020564560 A JP2020564560 A JP 2020564560A JP 2021526365 A5 JP2021526365 A5 JP 2021526365A5
Authority
JP
Japan
Prior art keywords
cell
hla
tumor
cell composition
subpopulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526365A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033182 external-priority patent/WO2019222760A1/en
Publication of JP2021526365A publication Critical patent/JP2021526365A/ja
Publication of JP2021526365A5 publication Critical patent/JP2021526365A5/ja
Pending legal-status Critical Current

Links

JP2020564560A 2018-05-18 2019-05-20 改善された標的化t細胞療法 Pending JP2021526365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862673745P 2018-05-18 2018-05-18
US62/673,745 2018-05-18
PCT/US2019/033182 WO2019222760A1 (en) 2018-05-18 2019-05-20 Improved targeted t-cell therapy

Publications (2)

Publication Number Publication Date
JP2021526365A JP2021526365A (ja) 2021-10-07
JP2021526365A5 true JP2021526365A5 (cg-RX-API-DMAC7.html) 2022-05-30

Family

ID=68541068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564560A Pending JP2021526365A (ja) 2018-05-18 2019-05-20 改善された標的化t細胞療法

Country Status (6)

Country Link
US (1) US20230002730A1 (cg-RX-API-DMAC7.html)
EP (1) EP3796923A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021526365A (cg-RX-API-DMAC7.html)
CN (1) CN112512538A (cg-RX-API-DMAC7.html)
CA (1) CA3100775A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019222760A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12188004B2 (en) 2012-05-08 2025-01-07 The Johns Hopkins University Cancer immunotherapy using transfusions of allogeneic, tumor-specific CD4+ T cells
CA3132353A1 (en) 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
CA2980039A1 (en) * 2015-03-20 2016-09-29 Children's National Medical Center Generating virus or other antigen-specific t cells from a naive t cell population
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
BR112019018307A2 (pt) 2017-03-03 2020-03-31 Treos Bio Zrt Plataforma para identificação de peptídeos imunogênicos baseada em população
KR20200026898A (ko) * 2017-07-07 2020-03-11 이매틱스 바이오테크놀로지스 게엠베하 Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
CN113329761A (zh) 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
WO2020146434A2 (en) * 2019-01-07 2020-07-16 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
US20220160767A1 (en) * 2019-05-31 2022-05-26 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
IL295241B1 (en) * 2020-02-10 2026-06-01 Univ Johns Hopkins Cancer immunotherapy using allogeneic and tumor-specific T-cell and CD4 cell transfusions
CN114524870A (zh) * 2020-11-23 2022-05-24 香雪生命科学技术(广东)有限公司 源自于ssx2抗原的短肽
WO2022140608A1 (en) 2020-12-23 2022-06-30 Mana Therapeutics Methods and delivery of allogeneic cell products
US20220323500A1 (en) * 2021-04-09 2022-10-13 Achilles Therapeutics Uk Limited Cancer immunotherapy
CN115677846A (zh) * 2021-07-27 2023-02-03 香雪生命科学技术(广东)有限公司 针对抗原ssx2的高亲和力t细胞受体
CN115819555A (zh) * 2021-09-17 2023-03-21 香雪生命科学技术(广东)有限公司 一种识别ssx2的高亲和力tcr
CN114478712B (zh) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
CN117986350B (zh) * 2023-02-23 2024-08-16 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
CN117402218B (zh) * 2023-12-15 2024-02-20 上海惠盾因泰生物科技有限公司 一种Survivin阳性肿瘤的个体化树突状细胞疫苗及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6805861B2 (en) * 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
EP1717245B1 (en) * 2005-04-26 2011-06-08 Immatics Biotechnologies GmbH T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
CA2772076A1 (en) * 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
WO2015070061A1 (en) * 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Anti-wt1/hla bi-specific antibody
US20170335290A1 (en) * 2014-10-31 2017-11-23 Baylor College Of Medicine Survivin specific t-cell receptor targeting tumor but not t cells
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
CA2980039A1 (en) * 2015-03-20 2016-09-29 Children's National Medical Center Generating virus or other antigen-specific t cells from a naive t cell population
CN118421557A (zh) * 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
US20200182884A1 (en) * 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses

Similar Documents

Publication Publication Date Title
Anderson III et al. Genetic models of human and mouse dendritic cell development and function
Gagelmann et al. Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Parkhurst et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results
JP2022543702A5 (cg-RX-API-DMAC7.html)
Wirsdörfer et al. Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells
Clavijo et al. Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells
Wang et al. One stone, two birds: the roles of Tim-3 in acute myeloid leukemia
Morris et al. Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancer by promoting NK cell, macrophage and T cell responses
JP2021526365A (ja) 改善された標的化t細胞療法
Papa et al. Acute leukaemia in patients treated for Hodgkin's disease
Auge et al. Microenvironment remodeling and subsequent clinical implications in diffuse large B-cell histologic variant of Richter syndrome
Musto et al. Primary plasma cell leukemia in the era of new drugs: has something changed?
Zhu et al. Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen–mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia
Marrero et al. Successful Use of Bortezomib–Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma
Ogasawara et al. Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single‐center phase I/II trial
Hoskins et al. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups
Planel et al. PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients
Thakral et al. Acute Myeloid Leukemia: An Update
Heß Checkpoint inhibition in non-Hodgkin's lymphoma
Leung Cyclin-A1 and neoantigen-specific T cells to target acute myeloid leukaemia
Bhamidipati et al. Epstein-Barr Virus–Induced CD30-Positive Diffuse Large B-Cell Lymphoma in a Patient With Mixed-Phenotypic Leukemia Treated With Clofarabine
Lad et al. Chronic lymphocytic leukemia: inception to cure: are we there?
Zhang et al. Ki-67 can predict the response to the gemcitabine, oxaliplatin and L-asparaginase regimen (GELOX) and prognosis in patients with nasal natural killer/T-cell lymphoma
Intergroup AbstractsDokumentation und Evaluation der Weiterbildung
Llopis-Hernandez et al. 445 Does tyrosine and serine phosphorylation of STAT3 drive cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa?